Inspection Record

US Specialty Formulations LLC — FDA 483 Findings

US FDAInspected 2017-10-25Published 2024-01-17 5 findingsComputer system validationTraining and personnelEquipment and facilityLaboratory and QC controlsLabeling and packaging

Inspectors James M MasonThe inspectors who signed the published document.Inspector lookup

View the regulator's official source The source document is always the basis for judgement.

Findings

1Computer system validation

Appropriate controls are not exercised over computers or related systems to assure that changes in master production and control records or other records are instituted only by authorized personnel.

2Training and personnel

Clothing of personnel engaged in the manufacturing, processing and packing of drug products is not appropriate for the duties they perform.

3Equipment and facility

Equipment and utensils are not cleaned and maintained at appropriate intervals to prevent contamination that would alter the safety, identity, strength, quality or purity ofthe drug product.

4Laboratory and QC controls

Laboratory records are deficient in that they do not include the signature of the second person reviewing the record for accuracy.

5Labeling and packaging

The container labels of your outsourcing facility's drug products are deficient.

About this record

Extracted automatically from the document US FDA published on 2024-01-17. The source is available at the link above.

This is a record of that moment. Inspection findings are usually followed by the company's response and corrective action, but this page does not know how that turned out. Do not read it as the current state; check the regulator's official announcements for the latest status.

Translation and classification are automated and may differ in nuance from the source.

Other records for this company

US Specialty Formulations LLC company profile — full history US FDA documents, 2024 Go to Findings search